vapendavir
Phase 2- Indications
- Rhinovirus upper respiratory infections
Company intelligence / Profile preview
Aviragen Therapeutics
Alpharetta, Georgia, United Statesinvestors.vaxart.com ↗
- Ownership
- Public · VXRT
- Employees
- ~200
- Development stage
- Phase 2
01
Overview
Aviragen had several Phase 2 clinical programs including vapendavir (failed Phase 2b SPIRITUS study in asthma patients with rhinovirus infection), BTA585/enzaplatovir (failed to reduce viral load in Phase 2a RSV challenge study), and teslexivir/BTA074 (completed patient enrollment in Phase 2 trial for condyloma treatment with results expected in Q2 2018)[6][9]
- Therapeutic areas
- PulmonologyInfectious Diseases
- Modalities
- Small moleculesdirect-acting antivirals
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Georgia State University Research Foundation
04
Financials
- Market cap
- $117.9M
- Total revenue
- $27.2M
- Enterprise value
- $61.7M
Beyond the preview
Go deeper on Aviragen Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aviragen Therapeutics.